Search
for
Sort by
Research 211–240 of 1000+
- Reply to ‘What is the effect of obesity on the folliculosebaceous unit?’
- News-Screen Menopause: Haarausfall in der Menopause
- Botanical Treatment for Polycystic Ovary Syndrome
- New onset of alopecia in a young woman with end-stage renal disease
- Children and the Quality of Ambulatory Care
- [Hirsutism].
- Hirsutism
- Oral Contraception and the Treatment of Acne: Where are we?
- A comparative analysis of three explanatory models of mental disorder and a preferred focus of explanation
- Female pattern hair loss
- Polycystic Ovary Syndrome: It’s Not Just Infertility
- Female Pattern Hair Loss: Clinical features
- Precocious puberty: the unlikely herald of Familial adenomatous polyposis in a young girl
- MENSTRUAL DISORDERS IN ADOLESCENTS
- Acanthosis nigricans, insulin resistance and cutaneous virilism
- Hypertrichosis induced by latanoprost
- Gonadotropin-Releasing Hormone Agonist Treatment in Postmenopausal Women with Hyperandrogenism of Ovarian Origin
- Cutaneous manifestations of polycystic ovary syndrome: A cross-sectional clinical study
- Cholesterol homeostasis: Links to hair follicle biology and hair disorders
- Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic
- New onset alopecia and hirsutism in a postmenopausal women
- Activity of type 1 5α-reductase is greater in the follicular infrainfundibulum compared with the epidermis
- Strumal Carcinoid Tumor of the Ovary
- Indirect clinical markers for the detection of anabolic steroid abuse beyond the conventional doping control in athletes
- Skin manifestations of polycystic ovary syndrome
- Cutaneous manifestation of polycystic ovary syndrome
- New Criteria for the Clinical Diagnosis of Hyperandrogenism in Polycystic Ovarian Syndrome and the Risk of Overdiagnosis
- Machine learning-based steroid metabolome analysis reveals three distinct subtypes of polycystic ovary syndrome and implicates 11-oxygenated androgens as major drivers of metabolic risk
- [Cutaneous effects in hormonal contraception].
- [Clinical findings with a low-dosed antiandrogene (cyproteronacetate) and aethinyloestradiol women with virilising symptoms (author's transl)].